Literature DB >> 25616665

MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.

Yang Zhang1, Liying Geng2, Geoffrey Talmon3, Jing Wang4.   

Abstract

Development of drug resistance is one of the major causes of colorectal cancer recurrence, yet mechanistic understanding and therapeutic options remain limited. Here, we show that expression of microRNA (miR)-520g is correlated with drug resistance of colon cancer cells. Ectopic expression of miR-520g conferred resistance to 5-fluorouracil (5-FU)- or oxaliplatin-induced apoptosis in vitro and reduced the effectiveness of 5-FU in the inhibition of tumor growth in a mouse xenograft model in vivo. Further studies indicated that miR-520g mediated drug resistance through down-regulation of p21 expression. Moreover, p53 suppressed miR-520g expression, and deletion of p53 up-regulated miR-520g expression. Inhibition of miR-520g in p53(-/-) cells increased their sensitivity to 5-FU treatment. Importantly, studies of patient samples indicated that expression of miR-520g correlated with chemoresistance in colorectal cancer. These findings indicate that the p53/miR-520g/p21 signaling axis plays an important role in the response of colorectal cancer to chemotherapy. A major implication of our studies is that inhibition of miR-520g or restoration of p21 expression may have considerable therapeutic potential to overcome drug resistance in colorectal cancer patients, especially in those with mutant p53.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  5-FU; Apoptosis; Colorectal Cancer; Drug Resistance; MicroRNA (miRNA); miR-520g; p21; p53

Mesh:

Substances:

Year:  2015        PMID: 25616665      PMCID: PMC4358260          DOI: 10.1074/jbc.M114.620252

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  Restoration of p53/miR-34a regulatory axis decreases survival advantage and ensures Bax-dependent apoptosis of non-small cell lung carcinoma cells.

Authors:  Samik Chakraborty; Minakshi Mazumdar; Shravanti Mukherjee; Pushpak Bhattacharjee; Arghya Adhikary; Argha Manna; Sreeparna Chakraborty; Poulami Khan; Aparna Sen; Tanya Das
Journal:  FEBS Lett       Date:  2014-01-18       Impact factor: 4.124

Review 4.  Chemotherapy of gastrointestinal cancer.

Authors:  C G Moertel
Journal:  N Engl J Med       Date:  1978-11-09       Impact factor: 91.245

5.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

6.  Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage.

Authors:  W J Slichenmyer; W G Nelson; R J Slebos; M B Kastan
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

Review 7.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

8.  Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Authors:  Abde M Abukhdeir; Michele I Vitolo; Pedram Argani; Angelo M De Marzo; Bedri Karakas; Hiroyuki Konishi; John P Gustin; Josh Lauring; Joseph P Garay; Courtney Pendleton; Yuko Konishi; Brian G Blair; Keith Brenner; Elizabeth Garrett-Mayer; Hetty Carraway; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

9.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Authors:  P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose.

Authors:  D D Boyd; A E Levine; D E Brattain; M K McKnight; M G Brattain
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

View more
  46 in total

1.  Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.

Authors:  Esterina D'Asti; Annie Huang; Marcel Kool; Brian Meehan; Jennifer A Chan; Nada Jabado; Andrey Korshunov; Stefan M Pfister; Janusz Rak
Journal:  Am J Pathol       Date:  2015-12-12       Impact factor: 4.307

Review 2.  Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Authors:  Rongrong Liao; Yuexia Lin; Lihui Zhu
Journal:  Mol Biol Rep       Date:  2018-09-07       Impact factor: 2.316

Review 3.  MicroRNAs are important regulators of drug resistance in colorectal cancer.

Authors:  Yang Zhang; Jing Wang
Journal:  Biol Chem       Date:  2017-07-26       Impact factor: 3.915

4.  miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.

Authors:  Xiaoli Yuan; Rongjun Ma; Shiwei Yang; Li Jiang; Zhen Wang; Zunmin Zhu; Hongwei Li
Journal:  Cell Cycle       Date:  2019-06-20       Impact factor: 4.534

5.  New insights into tumor dormancy: Targeting DNA repair pathways.

Authors:  Elizabeth B Evans; Shiaw-Yih Lin
Journal:  World J Clin Oncol       Date:  2015-10-10

6.  CRCT1 regulated by microRNA-520 g inhibits proliferation and induces apoptosis in esophageal squamous cell cancer.

Authors:  Ning Wu; Yang Song; Liewen Pang; Zhiming Chen
Journal:  Tumour Biol       Date:  2015-12-30

7.  DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1.

Authors:  Shun Xu; Haijiao Huang; Yu-Ning Chen; Yun-Ting Deng; Bing Zhang; Xing-Dong Xiong; Yuan Yuan; Yanmei Zhu; Haiyong Huang; Luoyijun Xie; Xinguang Liu
Journal:  Cell Cycle       Date:  2016-08-25       Impact factor: 4.534

Review 8.  Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.

Authors:  María Antonia Lizarbe; Jorge Calle-Espinosa; Eva Fernández-Lizarbe; Sara Fernández-Lizarbe; Miguel Ángel Robles; Nieves Olmo; Javier Turnay
Journal:  Biomed Res Int       Date:  2017-05-10       Impact factor: 3.411

Review 9.  MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.

Authors:  Xin Yu; Zheng Li; Jun Yu; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-07-22       Impact factor: 6.831

10.  Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.

Authors:  Yang Zhang; Yi Zhang; Liying Geng; Haowei Yi; Wei Huo; Geoffrey Talmon; Yeong C Kim; San Ming Wang; Jing Wang
Journal:  J Biol Chem       Date:  2016-06-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.